secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088391
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology to Advance Onvansertib to First-Line mCRC, Partners with Pfizer Ignite for New Trial
--------------------------------------------------------------------------------

- Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.
- Launches CRDF-004 Phase 2 trial with 90 patients; interim topline results expected mid-2024.
- Pfizer Ignite will support clinical execution; expands relationship from Pfizer's 2021 equity investment.
- Discontinues ONSEMBLE second-line trial to focus resources on first-line program.
- Cash position of $89.4M as of June 30, 2023, sufficient to fund operations into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/0001104659-23-088391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/tm2322922d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer